{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:32:32Z","timestamp":1785439952603,"version":"3.56.0"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Bruton's tyrosine kinase inhibitors (BTKi) reduce mortality and morbidity in chronic lymphocytic leukaemia (CLL) but have an association with cardiotoxicities, including hypertension, atrial fibrillation (AF), ventricular arrhythmias (VA) and bleeding. There is currently no specific advice for Australian and New Zealand clinicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>In this paper, we aim to provide evidence\u2010based recommendations for risk assessment, monitoring and managing cardiovascular (CV) toxicity to optimise patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multidisciplinary roundtable was held on 21 August 2023 to discuss clinical evidence and derive consensus recommendations, which were graded according to class and level of evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline CV risk assessment, including patient history, blood pressure (BP), pulse and ECG, is recommended in all patients before starting a BTKi. Management and monitoring requirements should reflect the patient's risk status. A target BP of 140\/90\u2009mmHg should be achieved (or 130\/80\u2009mmHg in high\u2010risk patients or those with CV disease). In patients with pre\u2010existing AF, closer monitoring is recommended in consultation with cardiology. Oral anticoagulation is generally warranted in patients with a CHA2DS2\u2010VASc score of \u22652 in males or \u22653 in females. BTKi should be withheld for 3\u2009days before and after a minor procedure and 7\u2009days prior to or post a major procedure. Due to the risk of VA and sudden death, BTKi is generally contraindicated in patients with previous VA, severe or uncontrolled heart failure or hypertension. Multidisciplinary care aims to minimise complications and improve treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Further research should be directed at validating CV screening tools and measuring outcomes based on these recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.70159","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T12:23:46Z","timestamp":1753532626000},"page":"1556-1569","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"Department of Haematology University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Berkahn","sequence":"additional","affiliation":[{"name":"Auckland Hospital  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-2931","authenticated-orcid":false,"given":"Kyle","family":"Crassini","sequence":"additional","affiliation":[{"name":"Mid North Coast Cancer Institute  Coffs Harbour Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui\u2010Peng","family":"Lee","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-917X","authenticated-orcid":false,"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[{"name":"Princes Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Mulligan","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nolan","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Baker Heart and Diabetes Institute  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Haematology Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[{"name":"Newcastle Centre of Excellence in Cardio\u2010Oncology Hunter Medical Research Institute, Hunter New England Local Health District, University of Newcastle and Calvary Mater Newcastle  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001049"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.287"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-742437"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01102-1"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17788"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"e_1_2_6_32_1","unstructured":"Australian Institute of Health and Welfare (AIHW).National Indigenous Australians Agency.Aboriginal and Torres Strait Islander Health Performance Framework. 1.05 Cardiovascular disease. [cited 2024 April 15]. Available from URL:https:\/\/www.indigenoushpf.gov.au\/measures\/1-05-cardiovascular-disease."},{"key":"e_1_2_6_33_1","unstructured":"Australian Institute of Health and Welfare (AIHW) National Indigenous Australians Agency.Aboriginal and Torres Strait Islander Health Performance Framework. Section 3.14 Access to services compared with need. [cited 2024 April 15]. Available from URL:https:\/\/www.indigenoushpf.gov.au\/measures\/3-14-access-services-compared-with-need#:~:text=In%202018%E2%80%9319%2C%20in%20non 14.19."},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000404"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T16:06:05Z","timestamp":1757520365000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/imj.70159"],"URL":"https:\/\/doi.org\/10.1111\/imj.70159","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}